In conclusion, this study explored a novel c‐Mpl transport model and demonstrated that the combination of adiponectin with thrombopoietic agents may be an effective strategy for the treatment of ITP (Scheme1). The gene discussed is MPL; the disease is autoimmune thrombocytopenic purpura.